
The Library
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial
Tools
Irish Critical Care Trials Group (Including: McAuley, Daniel F., Laffey, John G., O'Kane, Cecilia M., Cross, L. J. Mark, Perkins, Gavin D., Murphy, Lynn, McNally, Christine, Crealey, Grainne and Stevenson, Michael). (2012) Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial. Trials, Vol.13 (No.1). p. 170. doi:10.1186/1745-6215-13-170 ISSN 1745-6215.
|
Text
WRAP_Perkins_1745-6215-13-170.pdf Download (1080Kb) | Preview |
Official URL: http://dx.doi.org/10.1186/1745-6215-13-170
Abstract
Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure. There are in vitro, animal studies and pre-clinical data suggesting that statins may be beneficial in ALI. The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI.
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year